Xeljanz, Rinvoq, and Olumiant Lawsuits for Heart Attacks, Strokes, Cancers, Deaths
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Xeljanz (tofacitinib), Rinvoq (upadacitinib), and Olumiant (baricitinib) are three Janus kinase (JAK) inhibitors approved by the FDA for treatment of rheumatoid arthritis as well as other medical conditions. Xeljanz is a Pfizer drug, Rinvoq is an AbbVie drug, and Olumiant is an Eli Lilly drug.
In December 2021 these drug companies revised the “Black-Box” warnings for Xeljanz, Rinvoq, and Olumiant to include more information about the increased risk of various adverse drug reactions, including serious heart-related events, cancer, blood clots, and death.
Our law firm is investigating possible drug injury lawsuits for patients who used Xeljanz, Rinvoq, or Olumiant and then suffered one of the serious side effects associated with these JAK inhibitors drugs. In particular, heart problems such as heart attacks, strokes, pulmonary embolism (PE), and deep vein thrombosis (DVT), as well as cancers such as lymphoma and lung cancer.
According to the FDA, some of the serious side effects and adverse drug events related to Xeljanz, Rinvoq, and Olumiant are:
- Heart Attacks
- Myocardial Infarction (MI)
- Strokes — Ischemic / due to a blood clot
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Arterial Thrombosis
- Lung Cancer
- Other Cancers
As stated above, our law firm is investigating possible Xeljanz, Rinvoq, and Olumiant lawsuits for patients who have suffered serious side effects or adverse drug reactions. We would like to help you or someone you know with a Xeljanz, Rinvoq, or Olumiant drug injury case. Please feel free to contact us, at your convenience.
Free Xeljanz, Rinvoq, and Olumiant Case Evaluation
We encourage you to submit a Xeljanz, Rinvoq, and Olumiant Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about your possible Xeljanz lawsuit. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Xeljanz, Rinvoq, and Olumiant
Xeljanz, Rinvoq, and Olumiant Safety Review by European Drug Regulator EMA
The JAK inhibitors drug class safety issue has landed in Europe, as indicated by this European Medicines Agency (EMA) February 11, 2022, news item, “EMA starts safety review of Janus kinase inhibitors for inflammatory disorders”. This Xeljanz, Rinvoq, and Olumiant safety review by the EMA follows a December 2021 JAK inhibitors drug class safety FDA action in the US, with Xeljanz, Rinvoq, and Olumiant getting revised drug labels adding more side effects warnings and more drug use restrictions.
Consistent with the December 2021 JAK inhibitors label changes mandated by the FDA here in the US, this February 2022 EMA Xeljanz, Rinvoq, and Olumiant safety review focuses on these JAK inhibitors as treatments for inflammatory disorders.
To read more of this article, click below:
From the above-referenced EMA news item:
The review was prompted by the final results from a clinical trial (study A3921133) of the JAK inhibitor Xeljanz (tofacitinib). The results showed that patients taking Xeljanz for rheumatoid arthritis and who were at risk of heart disease were more likely to experience a major cardiovascular problem (such as heart attack, stroke or death due to cardiovascular disease) and had a higher risk of developing cancer than those treated with medicines belonging to the class of TNF-alpha inhibitors….
In addition, preliminary findings from an observational study involving another JAK inhibitor, Olumiant (baricitinib), also suggest an increased risk of major cardiovascular problems and VTE in patients with rheumatoid arthritis treated with Olumiant compared with those treated with TNF-alpha inhibitors.
Our law firm is investigating possible drug injury lawsuits involving Xeljanz, Rinvoq, and Olumiant for patients who have suffered serious side effects or adverse drug reactions. Feel free to contact us if you or someone you know might have a Xeljanz, Rinvoq, or Olumiant drug injury case.
And, of course, we will continue to watch for future developments related to JAK inhibitors drug class safety and JAK inhibitors label changes.[Read article in full at original source]
Earlier articles about Xeljanz, Rinvoq, and Olumiant by attorney Tom Lamb on the Side Effects Blog:
- Xeljanz Safety Study Final Findings Presented in January 2022
- Xeljanz Safety Alert for People Who Are (1) Older, (2) Current / Past Smokers, or (3) With Cardiovascular or Cancer Risk Factors
- Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq
- Olumiant and Those JAK Inhibitors Drug Safety Issues: Eli Lilly’s “Spin”
- Drug Regulator MHRA Imposes More Xeljanz Use Limitations in October 2021
- Possible New Xeljanz Side Effect: Peripheral Neuropathy
- Xeljanz: Heart Attacks, Strokes, Cancers, Blood Clots, and Deaths – Updated FDA Warnings 2021
- FDA Advisory Committee Meeting Could Review Risk/Benefit Profiles for All JAK Inhibitors
- Possible FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq in Future
- Are Heart Problems and Cancers JAK Inhibitors Drug Class Safety Issues?
- New Xeljanz Warnings From FDA in 2021; Are Other JAK Inhibitors Next?
- Xeljanz 2021 FDA Warnings: Xeljanz Causing Heart Problems and Xeljanz Causing Cancer
- Xeljanz Side Effects Include Blood Clots, Pulmonary Embolism, And Serious Infections
- Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots
- Xeljanz FDA Drug Safety Communication About Increased Risks of Blood Clots And Death
- Serious Side Effects For Xeljanz 10 mg Dose Leads To European Drug Safety Regulatory Action
- Xeljanz Used For Ulcerative Colitis May Increase Risk Of Pulmonary Embolism
More articles about Xeljanz, Rinvoq, and Olumiant on our Drug Safety Developments website:
- Black Box Warning Label Added to JAK Inhibitors Including Xeljanz, Rinvoq and Olumiant
- Health Canada Issues Safety Review for Xeljanz in April 2021
- Xeljanz Safety Trial Results Which May Lead to Xeljanz Recall
- Will There Be a Xeljanz Recall in the Future?